Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.

Current medical research and opinion - 1 Jun 2017

Akerley Wallace L, Arnaud Alix M, Reddy Bibas, Page Ray D

Abstract excerpt

OBJECTIVE: The VeriStrat 1 (VS) test is intended to help guide treatment decisions for patients with advanced non-small-cell lung cancer (NSCLC) without an EGFR-sensitizing mutation, classifying patients into two categories. Patients classified as VSGood have a favorable prognosis and significant clinical response to EGFR tyrosine kinase inhibitors (TKIs). Patients classified as VSPoor have a less favorable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proteomics

Source

Identifiers

PMID: 28277859
DOI: 10.1080/03007995.2017.1301903

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer.PMID 28277859Read ↗

Incongruence Between Prerequisite Molecular Testing and Treatment with Personalized Therapies for Non-Small Cell Lung Cancer: A Surveillance, Epidemiology and End Results-Medicare Study.Semantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Interpretation of Lung Cancer Plasma EGFR Mutation Tests in the Clinical Setting.Semantic proximity Read ↗

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.Semantic proximity Read ↗

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review.Semantic proximity Read ↗

EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.Semantic proximity Read ↗

Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.Semantic proximity Read ↗

Molecular Pathology Testing for Non-small Cell Lung Cancer: An Observational Study of Elements Currently Present in Request Forms and Result Reports and The Opinion of Different StakeholdersSemantic proximity Read ↗

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in PracticeSemantic proximity Read ↗

Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.Semantic proximity Read ↗

Molecular & Translational Biology of the Blood-Based VeriStrat® Proteomic Test Used in Cancer Immunotherapy Treatment GuidanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.